Dragging Ras Back in the Ring

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

ras GENES

Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,541

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043

GEFs and GAPs: Critical Elements in the Control of Small G Proteins

Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903

Ras oncogenes: split personalities

Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467

A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants

Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Abou‐Alfa, G. K., Schwartz, L. H., Ricci, S., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Douillard, J., Lathia, C. D., Schwartz, B. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195

Downstream Signaling of the Sos Gene is Not Required during the Pathogenesis of Cancer Cells Bearing KRAS and BRAF Mutations

Tamimi, Y., & Busaidi, A. A. (2015) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000240 · Cited by 1

Production of authentic geranylgeranylated KRAS4b using an engineered baculovirus system

Procter, L. V., Grose, C., & Esposito, D. (2018) · Protein Expression and Purification · doi:10.1016/j.pep.2018.06.012 · Cited by 1

Exploring Protein-Ligand and Protein-Protein Interactions

Skern, T. (2018) · Learning materials in biosciences · doi:10.1007/978-3-319-76858-8_6 · Cited by 1

Neoadjuvant treatment of pancreatic ductal adenocarcinoma: present and future

Koukourakis, I. M., Desse, D., Papadimitriou, M., Konstadoulakis, M. M., Zygogianni, A. G., & PAPADIMITRIOU, C. A. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.43 · Cited by 1

Studying RAS Interactions in Live Cells with BRET

Columbus, J., & Turbyville, T. J. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3822-4_18 · Cited by 1

Affinity Measurement of Non-covalent Interactions of the Covalent KRAS G12C GDP Inhibitor MRTX849 to RAS Isoforms Using Surface Plasmon Resonance

Alexander, P., & Stephen, A. G. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3822-4_8 · Cited by 2

An updated patent review of SOS1 inhibitors (2022–present)

Zhou, G., Zhou, C., Ma, X., Xu, J., Zhou, Z., Xu, T., Zheng, M., & Zhang, S. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2419825 · Cited by 1

Biogenesis of extracellular vesicles and their role in cancer

Sharma, S., Singh, A. N., & Rana, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95258-3.00004-7 · Cited by 1

Etio-pathogenesis I

Bignold, L. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801565-0.00004-4 · Cited by 1

Targeted Therapy and Precision Medicine

Tasian, S. K., & Hunger, S. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-39708-5_8 · Cited by 1

Targeted Therapy in Advanced Melanoma

Sosman, J. A., & Johnson, D. B. (2018) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_12-1 · Cited by 1

Emerging Technologies for the Diagnosis and Treatment of Pancreatic Cancer

Swierczewska, M., Козлов, С. В., & Adiseshaiah, P. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00022-3 · Cited by 1

Postchemotherapy sarcoma as a somatic-type malignancy derived from the gonadal yolk sac tumor in a patient with 46, XY pure gonadal dysgenesis

Zong, X., Yang, J., Zhang, Y., Cao, D., Shen, K., You, Y., & Guo, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s192111 · Cited by 1

Targeting der kleinen GTPasen über ihre regulatorischen Proteine

Gray, J. L., von Delft, F., & Brennan, P. E. (2019) · Angewandte Chemie · doi:10.1002/ange.201900585 · Cited by 1

Drosophila Cancer Modeling Using the Eye Imaginal Discs

Gangwani, K., Snigdha, K., Atkins, M., Singh, S. R., & Kango‐Singh, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-42246-2_9 · Cited by 2

Oncogenic G12D mutation alters local conformations and dynamics of K-RasPreprint

Vatansever, S., Erman, B., & Gumus, Z. H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/178483 · Cited by 1

Anoikis Regulation: Complexities, Distinctions, and Cell Differentiation

Beauséjour, M., Boutin, A., & Vachon, P. H. (2018) · Wiley eBooks · doi:10.1002/9781119432463.ch8 · Cited by 1

Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants

Ly, S. H. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1

KRAS signalling in malignant pleural mesotheliomaPreprint

Marazioti, A., Blanquart, C., Krontira, A. C., Pepe, M. A. A., Hackl, C. M., Iliopoulou, M. P., Lamort, A., Koch, I., Lindner, M., Hatz, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.22.350850 · Cited by 1

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RASPreprint

Ilter, M., Kaşmer, R., Jalalypour, F., Atılgan, C., Topcu, O., Karakaş, N., & Şensoy, Ö. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.24.489309 · Cited by 1

Hexokinase 1b is a novel target for Non–small-cell lung cancerPreprint

Yozgat, Y., Karakoç, E., Şahin, Ö., Çimen, Ş., Rabeh, W. M., Aydın, M. Ş., Mardinoğlu, A., Gürsel, İ., Çakır, A., Şensoy, Ö., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.27.497447 · Cited by 2

pH-responsive Targeted nanoparticles release ERK-inhibitor in the hypoxic zone Sensitizes Gemcitabine in Mutant K-Ras-addicted Pancreatic CancerPreprint

Dutta, D., De, A., Ghosh, A., Hazra, R. S., Ghosh, P., Banerjee, S., DÍAZ, F. J., Upadhyay, S. P., Quadir, M., & Banerjee, S. K. (2023) · Research Square · doi:10.21203/rs.3.rs-2909446/v1 · Cited by 1

Targeting oncogenic K-Ras mutants with a small-molecule degrader through Nedd4-1Preprint

Zeng, T., Jiang, T., Zhang, B., Zhang, T., Dai, W., Yin, X., Li, Y., Wu, C., Wu, Y., Chi, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.26.591418 · Cited by 1

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesPreprint

Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Morris, J., Takebe, N., Doroshow, J. H., & Teicher, B. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.17.623998 · Cited by 1

Engineered subtilisin protease degrades active KRAS in cancer cells, leading to differential cell targetingPreprint

Goldstein, M. E., Chu, B., Carillo, K. J., Orban, J. P., Toth, E. A., & Fuerst, T. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.04.709402 · Cited by 1

RAS Genes and Cancer

Hayes, T. K., Stratford, J. K., Wang‐Gillam, A., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_7

Novel Posttranslational Modification in LKB1 Activation and Function

Lee, S.-W. (2014) · Digital Commons-TMC (Texas Medical Center)

JB Review Activated K-RAS and its effect on morphological appearance

Kiyokawa, E., & Minato, H. (2014)

Etio-Pathogenesis III

Bignold, L. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801565-0.00006-8

Exploiting Cancer Cell Signaling and Metabolism: Implications for Therapeutic Approach

Mukhopadhyay, S. (2015) · CUNY Academic Works (City University of New York) · doi:10.13140/rg.2.1.4721.3848

Ranking small molecules by how much they

Langham, J. J. (2014)

Cross Talk Between Snail and Mutant K-Ras Contributes to Pancreatic Cancer Progression

Chow, C. R., Ebine, K., Hattaway, H. Z., Kumar, K., & Munshi, H. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00007-2

Fortschritte bei der Ras‐Inhibition aus medizinisch‐chemischer Perspektive

Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie · doi:10.1002/ange.201608270

Patterns of cancer somatic mutations predict genes involved in phenotypic abnormalities and genetic diseasesPreprint

Provero, P., Molineris, I., Lazarević, D., & Cittaro, D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/120121

Cryptorchidism and Precocious Puberty in a Patient with Noonan Syndrome and 21-Hydroxylase Deficiency

Lichiardopol, C. (2015) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2015.356

Fam129b Phosphorylation And Its Effect On Membrane Localization In Confluent Hela Cells

Somasekharan, L. T. (2017)

O papel da autofagia no estresse oncogênico promovido por HRASG12V em queratinócitos humanos imortalizados por E6E7

Lopes, E. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2017.tde-21062017-084659

Natural language processing: put your model where your mouth is

Haggerty, R. A., & Purvis, J. E. (2017) · Molecular Systems Biology · doi:10.15252/msb.20178077

Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma

Alon, M., Emmanuel, R., Qutob, N., Bakhman, A. F., Peshti, V., Brodezki, A., Bassan, D., Kosloff, M., & Samuels, Y. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12705

Somatic mutability in cancer predicts the phenotypic relevance of germline mutationsPreprint

Provero, P., Lazarević, D., & Cittaro, D. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/447862 · Cited by 1

Effects of Localized EphB2 Stimulation on Dendritic Filopodia of Hippocampal Neurons

Locke, C. (2018) · OpenCommons at University of Connecticut (University of Connecticut)

Explorando a quinase IKK como um alvo terapêutico para células iniciadoras de tumor pulmonares induzidas pelo oncogene KRAS

Rodrigues, F. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2018.tde-26112018-080111

Quantitative Proteomics to Support Translational Cancer Research

Hoffman, M. A. (2018) · Digital Commons - University of South Florida (University of South Florida)

Regulation of the kRAS Promoter in Pancreatic Cancer by Proteins and Small Molecules

Batra, H. (2017) · ProQuest Demo Repository

TARGETING THE ERK MAPK PATHWAY IN RAS-DRIVEN CANCERS

Ryan, M. B. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/jjj1-7f72

Growth of cells, growth factors, and oncogenes

Bignold, L. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816920-9.00004-3

Hereditary predispositions to tumors, tumor suppressor genes, and their clinico-genomic complexities

Bignold, L. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816920-9.00005-5 · Cited by 1

The phylogenetic functional conservation of Drosophila Seven-In-Absentia (SINA) E3 ligase and its two human paralogs, SIAH1 and SIAH2, in Drosophila eye developmentPreprint

Sciver, R. E. V., Cao, Y., & Tang, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.28.067074

Enabling in vivo Analysis Via Nanoparticle-mediated Intracellular Assay Probe Delivery: Using RAS as the PrototypePreprint

Chen, F., Liu, Q., Hilliard, T., Wang, T., Dong, Z., Li, W., Liang, H., Gao, W., Huang, L., & Wang, D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.05.188862

Targeting the EPHA2 receptor tyrosine kinase in KRAS and EGFR mutant lung cancer

Amato, K. R. (2015)

Alisertib exerts KRAS allele specific anticancer effects in colorectal cancerPreprint

Ren, B., Gao, Z., Zheng, K., Yang, Y., Su, P., Luo, Q., Feng, J. C., Luo, Z., Geng, Y., Ju, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.14.340125

The Role of Mdivi-1 in Colorectal Cancer

Wang, S. (2018) · TSpace (University of Toronto)

Immune-evasion of KRAS -mutant lung adenocarcinoma mediated by cAMP response element-binding proteinPreprint

Giotopoulou, G. A., Ntaliarda, G., Marazioti, A., Lilis, I., Kalogianni, F., Tourkochristou, E., Spiropoulou, N., Giopanou, I., Σπέλλα, Μ., Iliopoulou, M. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.19.449094

Mechanistic Insight on Ras Inhibition Strategies in Cancer Therapy

Anoosheh, J. P., Barzegar, A., Hejazi, M. S., Hasheminejad, N., Heidari, H. R., & Aghdam, E. M. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.25

Drug-development Strategy for Undruggable Targets Using a Novel Target Degradation Technology CANDDY

Miyamoto‐Sato, E., Imanishi, S., & Huang, L. (2022) · Journal of The Society of Japanese Women Scientists · doi:10.5939/sjws.22005

Drug Targets

Li, J. J. (2020) · Wiley eBooks · doi:10.1002/9781119607311.ch1

Applications of Constrained Helices

Li, Z., Zhao, H., & Wan, C. (2021) · Wiley eBooks · doi:10.1002/9783527343430.ch4

Ras Proteins☆

George, S., & Der, C. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98756-7

Cancer Dynamics

Gandía, D., & Suárez, C. A. (2020) · Cancer Studies and Molecular Medicine - Open Journal · doi:10.17140/csmmoj-6-130

Targeted Therapy in Advanced Melanoma

Sosman, J. A., & Johnson, D. B. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_12

IFNA pathway drives the more aggressive phenotype of KRAS G12D -mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activationPreprint

Inoue, K., Schanne, D. H., Matsui, A., Lei, P., Klein, S., Aoki, S., Taniguchi, H., Kikuchi, H., Jiang, C., Liu, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.29.497540

Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS

Dent, P., Poklepovic, A. S., & Booth, L. A. (2019) · EMJ Oncology · doi:10.33590/emjoncol/10314967

Discovery of a novel drug using lipid-based formulation targeting G12D-mutated KRAS4B through non-covalent bondsPreprint

Lu, H., Hu, Z., Faraudo, J., & Martí, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.05.535682 · Cited by 1

Preliminary exploration of the potential biological functions and prognosis values of RAB4B in pan-cancer combing with experimental validation in BLCA

Li, K., Liang, S., & Mi, H. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1840

Additional file 2 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells

Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175865

Atomic-scale mechanisms of GDP extraction by SOS1 in KRAS-G12 and KRAS-D12 oncogenesPreprint

Hu, Z., & Martı́, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.17.599303

Computational Analysis of Treatment Resistant Cancer CellsPreprint

Matov, A. (2024) · medRxiv · doi:10.1101/2024.08.29.24312813

Chromosomal and Genomic Alterations in Pediatric AML

Lamble, A. J., & Huang, B. J. (2024) · Pediatric oncology · doi:10.1007/978-3-031-63366-9_2

Introduction

Malek, S., & McCormick, F. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.02001-5

Somatic genetic alterations of oncogenes and tumor suppressor genes in cholesteatoma

Şi̇mşek, L., Yıldırım, M. S., Ülkü, Ç. H., & Zamanı, A. G. (2024) · Acta Oto-Laryngologica · doi:10.1080/00016489.2024.2433138

Revealing Functional Hotspots: Temperature-Dependent Crystallography of K-RAS Highlights Allosteric and Druggable SitesPreprint

Deck, S. L., Xu, M., Stankus, M., Milano, S. K., & Cerione, R. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.27.639303

Thyroid C-Cell Biology and Oncogenic Transformation

Bagheri‐Yarmand, R., Grubbs, E. G., & Hofmann, M.-C. C. (2025) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-031-80396-3_3

Real time characterization of the MAPK pathway using native mass spectrometry

Scott, E., Yun, S. D., Moghadamchargari, Z., Bahramimoghaddam, H., Chang, J., Zhang, T., Zhu, Y. K., Lyu, J., & Laganowsky, A. D. (2025) · Communications Biology · doi:10.1038/s42003-025-08028-5

Mechanism of Action and Research Progress of Drugs Targeting KRAS G12-Mutant Tumors

郑, 金. (2025) · World Journal of Cancer Research · doi:10.12677/wjcr.2025.152011

PTPRJ-Targeting Peptide Agonist Induces Broad Cellular Signaling Perturbations and DNA Damage in Lung Cancer CellsPreprint

Rizzo, S., Hart, W. S., Fetter, R. L., Song, B., White, F. M., Lazzara, M. J., & Thévenin, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.17.688709

Additional file 1 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells

Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175862

The role of autophagy in the face of the oncogenic stress triggered by HRASG12V in human keratinocytes immortalized by E6E7

Lopes-Cararo, E. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

Angelica sinensis promotes thymic cortical regeneration in mice with acute thymic involution induced by short-term rapamycin treatment

Xie, X. U., Shu, Y., & Gao, J. (2026) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2025-0396

An alginate-based 3D cell culture model as a useful tool for melanoma drug testing

Eckert, C., Schmidt, S. K., Sandor, E., Karimi, T., Arkudas, A., Kengelbach‐Weigand, A., & Bosserhoff, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119275

Development of tumour therapies : from target validation of TTLL12 to tests of a small molecule XRP44X in pre-clinical models of cancer

Semenchenko, K. (2014) · theses.fr (ABES) · doi:10.70675/80090366z28f9z4067za036zc31b95911a52

Cell penetrating and interfering peptides as new cancer therapy

Zhang, X. (2017) · theses.fr (ABES) · doi:10.70675/b2053021ze747z4f1azacb7z8a87a14ec9e3

Lighting up Invasion with Optogenetics : RalB Mobilizes the WRC Complex Downstream Ras

Zago, G. (2018) · theses.fr (ABES) · doi:10.70675/5530038ez9f6bz4870zb51ezdb058f3e56c0

Establishing a fly model to investigate the immune defenses against injection of oncogenic RASV12-GFP cells

Sinha, A. R. (2018) · doi:10.70675/51b304ebz0181z47ddz82c2ze564aed8f575

Rôle de la matrice extracellulaire et des récepteurs à domaine discoïdine, DDR1 et DDR2, dans la résistance des cellules de mélanome aux thérapies ciblées

Berestjuk, I. (2019) · theses.fr (ABES) · doi:10.70675/9e2ac6eczf91cz4121za391z89c897cdc4a0

Identification and Optimization of Pyridone Derivatives as Pan-MEK/RAF Nondegrading Molecular Glues for the Treatment of RAS-Driven Cancers

Wang, P. P., Yuan, Y., Yang, L., Sun, R., Bo, W., Ma, Z., Qin, S., Chen, Y., Li, M., Liu, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00242

Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic responsePreprint

Browne, A. T., McCann, C., McDaid, W. J., Lewis, N., Sridhar, S., Doherty, G. J., Moss, D. Y., Downs, M., Marry, S., Phillips, A. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.06.723208

High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study

Perkins, S. C., Krahnke, S., Larsen, E. K., Drew, M. R., Frank, P. H., Hong, M., Rabara, D., Wall, V. E., Grose, C., Gillette, W., et al. (2026) · Protein Expression and Purification · doi:10.1016/j.pep.2026.106950

Oncogenic Ras drives EED degradation and PRC2 dysfunction to promote aggressive squamous cell carcinoma

Li, M.-Y., Houser, A. E., Cheema, P. S., Zheng, X. Y., Restrepo, P., Flora, P., Zhou, Y., Segal-Dalal, G., Silberstein, E., Zhang, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75529-0

IMPACT OF KRAS MUTATION STATUS ON STEREOTACTIC RADIOSURGERY RESPONSE IN NON-SMAL CELL LUNG CANCER WITH BRAIN METASTASES

Karim, M. U., Martínez, C., Khan, A. M. H., Baksh, A. R., Joseph, A., Panet-Raymond, V., TSIEN, C., Kopek, N., & Abdulkarim, B. (2026) · Advances in Radiation Oncology · doi:10.1016/j.adro.2026.102176

Mechanism of neoantigen generation and advances in neoantigen-based immunotherapies in colorectal cancer

Wang, N., Xia, Y., Wang, P., He, Y., Zhao, K., & Zhang, Z. (2026) · Medical Oncology · doi:10.1007/s12032-026-03357-9

Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption

Yoshikawa, Y., Kubota, H., Matsumoto, S., Makino, Y., Kawamura, T., Yuki, H., Sakai, N., Shibaike, A., Okamura, M., Fujimoto-Sakisaka, W., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76337-2 · Cited by 1

Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development

Li, L., Li, J., Yang, L., Zhou, J., & Ma, Y. (2026) · Pharmaceuticals · doi:10.3390/ph19091388

Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targetingPreprint

Fuerst, T. R., Goldstein, M., Chu, B., Carillo, K. J., Orban, J. P., & Toth, E. (2026) · Research Square · doi:10.21203/rs.3.rs-10438702/v1

Blockade of mutant RAS oncogenic signaling: A 2026 update

Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109669

BindingDB Entry 50020682: Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.

BindingDB (2024) · UC San Diego · doi:10.7270/q2k64pjx

BindingDB Entry 50018665: Targeting mutated GTPase KRAS in tumor therapies.

BindingDB (2024) · UC San Diego · doi:10.7270/q2qc07s4

BindingDB Entry 50006630: Covalent Guanosine Mimetic Inhibitors of G12C KRAS.

BindingDB (2020) · UC San Diego · doi:10.7270/q24f1trh

BindingDB Entry 50015546: Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-6-mer) Peptides.

BindingDB (2023) · UC San Diego · doi:10.7270/q2s186d0

BindingDB Entry 50008021: A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.

BindingDB (2021) · UC San Diego · doi:10.7270/q23x8b01

BindingDB Entry 50002522: Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer.

BindingDB (2020) · UC San Diego · doi:10.7270/q22j6fgp

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997

Ras and Ras Signaling as a Therapeutic Target in Cancer

Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2

Targeting the “undruggable” RAS with biologics

Whaby, M., Khan, I., & O’Bryan, J. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.006 · Cited by 19

Targeting the Undruggable: Small Molecule Modulation of Ras Proteins

Kim, J. (2025) · International journal of high school research · doi:10.36838/v7i9.103

RASpecting the oncogene: New pathways to therapeutic advances

Stout, M. C., & Campbell, P. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.022 · Cited by 7